KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $86 | $0 | $0 |
| Gross Profit | $0 | -$86 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $72 | $86 | $80 | $70 |
| G&A Expenses | $116 | $54 | $31 | $26 |
| SG&A Expenses | $116 | $54 | $31 | $26 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$86 | $0 | $0 |
| Operating Expenses | $188 | $54 | $111 | $97 |
| Operating Income | -$188 | -$140 | -$111 | -$97 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $8 | $5 | $18 | $14 |
| Pre-Tax Income | -$180 | -$135 | -$93 | -$82 |
| Tax Expense | $3 | -$8 | $0 | $0 |
| Net Income | -$183 | -$127 | -$93 | -$82 |
| % Margin | – | – | – | – |
| EPS | -3.69 | -3.44 | -3.33 | -3.36 |
| % Growth | -7.3% | -3.3% | 0.9% | – |
| EPS Diluted | -3.69 | -3.44 | -3.33 | -3.36 |
| Weighted Avg Shares Out | 50 | 37 | 28 | 24 |
| Weighted Avg Shares Out Dil | 50 | 37 | 28 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $0 | $2 | $1 |
| Interest Expense | $6 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$173 | -$134 | -$94 | -$81 |
| % Margin | – | – | – | – |